Healthcare costs

FDA Approves First Interchangeable Biologic | McDonnell Boehnen Hulbert & Berghoff LLP

Last week, the United States Food and Drug Administration approved an interchangeable biosimilar to insulin glargine, a remarkable approval because it is the first interchangeable biosimilar approved. The product is Semglee (insulin glargine-yfgn), produced by Mylan Pharmaceuticals, Inc., and by virtue of this approval, it is interchangeable with Lantus (insulin …

Read More »

Building confidence in AI for healthcare

Joachim Roski, Director of Booz Allen Hamilton Kathleen Featheringham, Director of Booz Allen Hamilton Better clinical decision support, population health interventions, personal patient care and research – these are just a few of the promising use cases for artificial intelligence (AI). In addition to its benefits, AI can introduce risks …

Read More »